| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Han Ma | Q59701570 |
| P2093 | author name string | Li-Hua Chen | |
| Lin Li | |||
| You-Ming Li | |||
| Zhe Shen | |||
| Chao-Hui Yu | |||
| P2860 | cites work | Metformin in non-alcoholic steatohepatitis. | Q43745120 |
| HOMA test in diabetic patients with simultaneous pancreas and kidney transplantation | Q43963110 | ||
| N-acetylcysteine in the treatment of non-alcoholic steatohepatitis | Q44585271 | ||
| A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis | Q44749300 | ||
| Metformin in the treatment of patients with non-alcoholic steatohepatitis | Q44778658 | ||
| Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study | Q44890155 | ||
| Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. | Q46085888 | ||
| Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. | Q46533800 | ||
| Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial | Q46553519 | ||
| Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study | Q46680959 | ||
| Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet | Q47355908 | ||
| Regulatory effects of bifidobacteria on the growth of other colonic bacteria | Q50146955 | ||
| Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis | Q51368607 | ||
| Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin | Q56627599 | ||
| Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease | Q61022732 | ||
| Hypocholesterolemic action of Lactobacillus acidophilus ATCC 43121 and calcium in swine with hypercholesterolemia induced by diet | Q73064986 | ||
| Effect of administration of Lactobacillus gasseri on serum lipids and fecal steroids in hypercholesterolemic rats | Q74307749 | ||
| A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis | Q78147915 | ||
| Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study | Q80101604 | ||
| Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial | Q82112174 | ||
| The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance? | Q83932867 | ||
| Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review | Q22242709 | ||
| Diversity of the human intestinal microbial flora | Q24544241 | ||
| Metagenomic analysis of the human distal gut microbiome | Q24633486 | ||
| An obesity-associated gut microbiome with increased capacity for energy harvest | Q27860515 | ||
| Microbial ecology: human gut microbes associated with obesity | Q27861004 | ||
| Gut flora in health and disease | Q28209082 | ||
| Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics | Q28303404 | ||
| The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis | Q28345942 | ||
| Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity | Q28512778 | ||
| Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance | Q29012156 | ||
| Human gut microbiota in obesity and after gastric bypass | Q29615813 | ||
| Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis | Q29619888 | ||
| Mechanisms of liver cell injury | Q33870222 | ||
| Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. | Q33910338 | ||
| Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. | Q34006689 | ||
| Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans | Q34152486 | ||
| PROBIOTICS: GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS. | Q34258740 | ||
| Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro | Q34522706 | ||
| Effects of consumption of probiotics and prebiotics on serum lipid levels in humans | Q34865812 | ||
| Probiotics, infection and immunity | Q35103834 | ||
| Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics | Q35114267 | ||
| Molecular analysis of the composition of the bifidobacterial and lactobacillus microflora of humans. | Q35196131 | ||
| Probiotics and human health: a clinical perspective | Q35520339 | ||
| Resource partitioning in relation to cohabitation of Lactobacillus species in the mouse forestomach | Q35896508 | ||
| Recent concepts in non-alcoholic fatty liver disease | Q36234172 | ||
| Weight loss as a treatment for nonalcoholic fatty liver disease | Q36422718 | ||
| The epidemiology of nonalcoholic fatty liver disease in adults | Q36422726 | ||
| Biological Effects of ω-3 Fatty Acids in Diabetes Mellitus | Q36923363 | ||
| A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). | Q37278117 | ||
| Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? | Q37347550 | ||
| Gut-Liver Axis and Sensing Microbes | Q37869765 | ||
| Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials | Q37978785 | ||
| Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis | Q38308819 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. | Q42466118 | ||
| Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy | Q43281074 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| liver disease | Q929737 | ||
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| probiotics | Q1816730 | ||
| fatty liver disease | Q6058862 | ||
| P304 | page(s) | 6911-6918 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis | |
| P478 | volume | 19 |
| Q26752487 | A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD |
| Q57494349 | A systematic review of the present and future of non-alcoholic fatty liver disease |
| Q34779049 | Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. |
| Q37574992 | Advances in Gut Microbiome Research, Opening New Strategies to Cope with a Western Lifestyle |
| Q36246821 | Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage |
| Q34425909 | Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer |
| Q35947349 | Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? |
| Q35586085 | Choline and Fructooligosaccharide: Non-alcoholic Fatty Liver Disease, Cardiac Fat Deposition, and Oxidative Stress Markers |
| Q58758202 | Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone? |
| Q45403785 | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease |
| Q26752614 | Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet |
| Q64929772 | Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. |
| Q26777658 | Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future |
| Q64067172 | Dose-dependent and strain-dependent anti-obesity effects of in a diet induced obese murine model |
| Q47945651 | Effect of 8-weeks prebiotics/probiotics supplementation on alcohol metabolism and blood biomarkers of healthy adults: a pilot study |
| Q35865699 | Effect of microbial cell preparation on renal profile and liver function among type 2 diabetics: a randomized controlled trial |
| Q38826535 | Effect of probiotics on body weight and body-mass index: a systematic review and meta-analysis of randomized, controlled trials |
| Q26764758 | Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials |
| Q35293427 | Effects of Probiotic Supplementation on Pancreatic β-cell Function and C-reactive Protein in Women with Polycystic Ovary Syndrome: A Randomized Double-blind Placebo-controlled Clinical Trial |
| Q47191893 | Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol |
| Q35920786 | Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials |
| Q26780254 | Endocrine causes of nonalcoholic fatty liver disease |
| Q34647400 | Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease |
| Q64119808 | Gut Microbiota Profiles in Nonalcoholic Fatty Liver Disease and Its Possible Impact on Disease Progression Evaluated with Transient Elastography: Lesson Learnt from 60 Cases |
| Q35616074 | Gut microbiome, gut function, and probiotics: Implications for health. |
| Q27015127 | Gut microbiota and liver diseases |
| Q24563886 | Gut microbiota and metabolic syndrome |
| Q28085158 | Gut microbiota and non-alcoholic fatty liver disease |
| Q35860576 | Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol |
| Q35998233 | Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice |
| Q61814448 | Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature |
| Q34499017 | Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease |
| Q35685083 | Gut-liver axis, nutrition, and non-alcoholic fatty liver disease |
| Q30665173 | Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability |
| Q64067048 | Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease |
| Q64099563 | Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials |
| Q47951112 | Increased Prevalence of Irritable Bowel Syndrome in a Cohort of French Morbidly Obese Patients Candidate for Bariatric Surgery. |
| Q35790409 | Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease |
| Q38787958 | Integrative Medicine for Gastrointestinal Disease |
| Q26863476 | Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective |
| Q59101131 | Is there a role for probiotics in liver disease? |
| Q97899581 | Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway |
| Q47608940 | Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture |
| Q37255995 | Metabolic Interactions in the Gastrointestinal Tract (GIT): Host, Commensal, Probiotics, and Bacteriophage Influences |
| Q91795154 | Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease |
| Q90575879 | Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease |
| Q26823918 | Modulation of the gut microbiota by nutrients with prebiotic and probiotic properties |
| Q94475580 | Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease |
| Q89895494 | Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma |
| Q37215934 | Non-alcoholic fatty liver and the gut microbiota |
| Q35728214 | Non-alcoholic fatty liver disease, diet and gut microbiota. |
| Q24563381 | Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic |
| Q26851211 | Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development |
| Q26771752 | Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease |
| Q38750137 | Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine |
| Q30434752 | Overview and recent trends of systematic reviews and meta-analyses in hepatology |
| Q28079432 | Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions |
| Q38845334 | Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease |
| Q92434553 | Prebiotics and probiotics in atopic dermatitis |
| Q36249192 | Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. |
| Q47709724 | Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial. |
| Q38408904 | Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease |
| Q38946102 | Probiotics for people with hepatic encephalopathy |
| Q26768518 | Probiotics in prevention and treatment of obesity: a critical view |
| Q60924499 | Protective effects of Bacillus probiotics against high-fat diet-induced metabolic disorders in mice |
| Q26778020 | Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease |
| Q92435669 | Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications |
| Q34440962 | Review article: the management of paediatric nonalcoholic fatty liver disease |
| Q26828765 | Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome |
| Q64125879 | Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis |
| Q48206905 | Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease |
| Q36775835 | Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation |
| Q38645789 | Starring role of toll-like receptor-4 activation in the gut-liver axis |
| Q46013546 | Stem cell intervention ameliorates epigallocatechin-3-gallate/lipopolysaccharide-induced hepatotoxicity in mice. |
| Q92307491 | Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease |
| Q35921869 | Targeting Dysbiosis for the Treatment of Liver Disease |
| Q33566385 | The Effect of Oral Consumption of Probiotics in Prevention of Heart Injury in a Rat Myocardial Infarction Model: a Histopathological, Hemodynamic and Biochemical Evaluation |
| Q36732958 | The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial |
| Q36751990 | The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease |
| Q41896010 | The Relationship Between the Gut Microbiota and Liver Disease |
| Q55450597 | The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. |
| Q64104402 | The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD |
| Q49174925 | The day will come to treat HCC in a drugstore? |
| Q89748115 | The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study |
| Q64980027 | The gut microbiome and nonalcoholic fatty liver disease. |
| Q26785649 | The gut microbiota and host health: a new clinical frontier |
| Q38643266 | The pharmacological management of NAFLD in children and adolescents |
| Q26852498 | The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease |
| Q53681665 | The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention |
| Q38782562 | Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview |
| Q26852403 | Treatment of nonalcoholic steatohepatitis in adults: present and future |
| Q39391152 | Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses. |
Search more.